ArticleEJNMMI research2026
Emerging need of dosimetry in radioligand therapy: a feasible method tested in a large cohort of patients affected by neuroendocrine neoplasms.
Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundRadioligand therapy is an important treatment option for neuroendocrine neoplasms. Although the use of internal dosimetry is recommended, its application in clinical routine is not widespread. This study aims to propose and evaluate a feasible method for determining the absorbed doses to organs at risk and tumour lesions in a large cohort of neuroendocrine neoplasm patients. Eighty patients who were treated as part of the FENET-2016 trial were enrolled in this study prospectively. The FENET-2016 protocol is based on two therapeutic schemes: a MONO therapy, consisting of five administrations (therapeutic cycles) of 177Lu-DOTATOC and a DUO therapy, consisting of three cycles of 177Lu-DOTATOC alternating with two cycles of 90Y-DOTATOC. A simplified method based on three-time-point SPECT/CT was first validated on a small cohort of patients and was then applied to all the eighty patients enrolled in the study to assess dosimetric evaluation for the organs at risk (kidneys, bone marrow, and tumours).
resultsSixty-nine patients underwent a complete dosimetric evaluation. Absorbed doses per administered activity and cumulative absorbed doses were reported for organs at risk and tumours, as well as biologically effective doses for organs at risk. The results of this study are consistent with published data from other groups. The cumulative absorbed dose to the kidneys exceeded the threshold reported in the literature in ten cases out of sixty-nine cases, while no cases of a cumulative absorbed dose exceeding 2 Gy to the bone marrow were reported. High variability in tumour absorbed dose per unit activity was observed.
conclusionsThe proposed simplified dosimetric approach is feasible and easy to implement in clinical practice. This study demonstrated that dosimetry is a useful clinical tool, as it enables clinicians to guide patients towards combined radionuclide treatment or multiple treatments, which could improve patient outcomes. CLINICAL
trial registration- EU Clinical Trials Register, EUDRACT Id: 2016-005129-35, 22 February 2018.
trial registrationEUDRACT 201,600,512,935, Registered 22 February 2018, https//www.clinicaltrialsregister.eu/ctrsearch/search? query=2016-005129-35.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.